EGFR and ALK mutations — why immunotherapy may not be for you

Because the cancer has a single identifiable driver. EGFR-mutant and ALK-rearranged lung cancers usually carry few mutations overall and attract few immune cells, so checkpoint inhibitor immunotherapy given alone has consistently low reported response rates in this group. NCCN and ESMO guidance therefore place a matched targeted tablet first, not immunotherapy.

Checkpoint inhibitors work by releasing a brake on immune cells that have already recognised the tumour as abnormal. That recognition depends on the tumour looking sufficiently foreign to the immune system. Cancers driven by one EGFR or ALK alteration typically have a low tumour mutational burden and a sparse immune infiltrate. There is less for the immune system to see, and fewer immune cells present to release.

This is also why a high PD-L1 score can mislead here. In lung cancer without a driver alteration, a high PD-L1 percentage is one of the main signals used to consider immunotherapy. In EGFR- and ALK-positive disease, the same percentage has not translated into comparable benefit in reported analyses, and guideline bodies do not treat it as an eligibility pass on its own.

For Indian patients this matters more than Western guidance suggests. Published Indian and other Asian series consistently report EGFR mutations in a far larger share of non-squamous non-small cell lung cancer than Western series — commonly around a quarter to a third of patients tested. ALK rearrangements are less common, in the low single digits. A large number of Indian lung cancer patients therefore land in exactly this group.

The reason this page exists is that people usually find this out late. A patient reads about immunotherapy for weeks, arranges the money, and then a molecular report arrives and the plan changes. Being told the rule before the first dose is scheduled makes it a decision rather than a rejection.

General patterns referenced from NCCN and ESMO non-small cell lung cancer guidance, indicative as of August 2026. Guidelines are revised periodically, and your own plan is set by your treating oncologist and tumour board — not by this table.

• Matched targeted tablets (tyrosine kinase inhibitors) — taken orally at home, aimed directly at the protein your alteration produces. Several generations of these drugs exist, and the right one depends on the exact change your report names, not on EGFR or ALK as a category.
• Platinum-based chemotherapy — the established next step once targeted options stop working, given as day-care cycles and chosen by histology.
• Anti-angiogenic therapy — drugs aimed at the tumour blood supply, used with chemotherapy in selected patients.
• Local treatment for limited progression — radiotherapy or a focused procedure to a single progressing site, which sometimes allows the current tablet to continue.
• Clinical trials — trials for EGFR- and ALK-positive lung cancer are among the most active in thoracic oncology. Enrolment is never guaranteed and a trial is not a promise of benefit, but asking whether one is open is reasonable at every decision point.

No brand or molecule is named here on purpose. The right drug depends on the exact alteration on your report and on current approval status with CDSCO, and that match is made by your treating oncologist rather than by a web page.

Yes, but rarely as a single drug and rarely first. In later lines, after targeted options are exhausted, some patients receive a chemotherapy-containing regimen that includes a checkpoint inhibitor. That decision is made case by case at a tumour board. Immunotherapy alone remains outside guideline recommendations for this group.

There is a safety reason for the order as well as an effectiveness one. Giving a checkpoint inhibitor shortly before starting an EGFR-targeted tablet has been associated in reported series with a higher rate of severe immune-related side effects, lung inflammation (pneumonitis) and liver inflammation in particular. Checkpoint inhibitors remain active in the body for weeks after the last dose, so the gap between the two matters.

If you are already on immunotherapy and a molecular report arrives late, that is not wasted treatment. It is a reason to bring both documents to a specialist review quickly, so the next step is planned around the timing of what has already been given.

Immunotherapy at CION is delivered as a day-care infusion at our centres. Molecular testing and response-assessment PET-CT are coordinated at accredited partner laboratories and imaging centres. What this page cannot tell you is whether immunotherapy belongs anywhere in your own sequence — that needs your report, your stage and your oncologist.

1. 1

   The full panel is run once, on one sample

   EGFR, ALK and the other actionable markers are tested together on the same biopsy wherever the tissue allows, so you are not called back for repeat procedures. Where tissue is inadequate, a blood-based ctDNA test can be used instead. Testing is coordinated at accredited partner laboratories.

2. 2

   The exact alteration is confirmed

   EGFR-positive is not one thing. Which exon and which specific change is present decides which tablet is appropriate, and the same is true for ALK. Your oncologist reads that line of the report, not just the headline.

3. 3

   Your tumour board reviews the whole picture

   Stage, histology, PD-L1, the molecular result, organ function and how you are actually feeling are weighed together in one meeting, instead of one doctor deciding alone.

4. 4

   A matched targeted therapy is started

   Usually as tablets taken at home, with scheduled reviews for side effects and blood tests. Most patients in this group do not need infusions at this stage of treatment.

5. 5

   Response and resistance are tracked

   Scans at planned intervals, coordinated at partner imaging centres, plus a symptom review at each visit. When a tablet stops working, repeat testing often identifies why, and that finding shapes the next line.

Ask two questions before anything else: was full molecular testing done, and has the result come back. If testing was never ordered, that is the gap to close first. If it came back positive for EGFR or ALK after immunotherapy started, the plan needs a specialist review, not a panic.

The frustration patients describe is rarely about the treatment itself. It is about being told one thing and then, weeks later, another — after money was arranged, leave was taken and family were told. Being given the eligibility rule at the start, in plain words, is what prevents that.

Two practical things are worth doing. Ask for the molecular report in writing and read which markers were actually tested, because a PD-L1 result on its own is not molecular testing. Then ask what the plan would be under each possible result, before the report arrives, so neither outcome is a surprise.

• Has my tumour been tested for EGFR and ALK, and for the other actionable markers? Ask for the report itself, not a verbal summary.
• Which exact alteration does my report name? The specific change decides which tablet fits, not the gene name alone.
• Was a PD-L1 score used to plan my treatment, and does my molecular result change how it is read?
• If I am driver-positive, what is the first treatment, and what happens when it stops working?
• Is immunotherapy planned at any point in my sequence, and if so, when and why?
• Is there a clinical trial open for my specific alteration? Ask at every decision point, not only at diagnosis.

• Pneumonitis Risk in Lung Cancer Patients on Immunotherapy — why lung inflammation is watched so closely in this cancer, and why the gap between a checkpoint inhibitor and a targeted tablet matters.
• Cost of Immunotherapy for Lung Cancer in India — what the numbers look like if immunotherapy does become part of your sequence later on.
• Immunotherapy for Melanoma: Why This Cancer Responds Best — the opposite end of the biomarker story, and a clear illustration of why response varies so much between cancer types.
• Immunotherapy at CION Cancer Clinics — how CION assesses eligibility, coordinates testing and supports patients through the decision.

This page explains general eligibility principles for education only and does not interpret any individual patient's report or name any specific medicine. Molecular testing is coordinated at accredited partner laboratories. Bring your reports to a consultation for a doctor's assessment of what they mean for you.

A mutation report is a direction, not a dead end

Families arrive here confused about why immunotherapy was ruled out. Our oncologists take the time to explain what your report means and what comes next.